Jeff P. Sharman, MD | Authors

Articles

Acalabrutinib Appears Tolerable in Chronic Lymphocytic Leukemia

April 02, 2020

Jeff P. Sharman, MD, discusses the secondary end points from the phase III ELEVATE-TN trial, which evaluated the role of acalabrutinib, either as a single agent or in combination with obinutuzumab in patients with treatment-naive chronic lymphocytic leukemia.